Loading
Hormonal Regulation and Hypertension / Adrenal and Paraganglionic Tumors / Pituitary Gland Disorders and Treatments · Journal article
European Journal of Endocrinology · August 11, 2026
Reinforces what was already believed, rather than introducing something new.
This multicenter RCT of 48 patients found that adrenalectomy for unilateral adrenal incidentalomas with MACS did not produce statistically significant improvements in weight loss, glycemic control, dyslipidemia, or quality of life compared to conservative management over 13 months, despite a prior benefit on hypertension in the same trial. The confidence intervals are wide and include null, and the authors acknowledge the sample is underpowered and call for larger studies to clarify the metabolic role of adrenalectomy.
Multicenter superiority open-label randomized controlled trial. Patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion. Baseline prevalence: 93% overweight/obese, 71% prediabetic/diabetic, 90% dyslipidemic.. Intervention: Adrenalectomy. Compared with: Conservative management. n = 48. Multicenter (specific locations not stated in abstract)..
21% of adrenalectomized versus 4% of conservatively treated overweight/obese patients achieved >5% weight loss (difference 22%, 95% CI: -2% to 39%, not significant) 44% of adrenalectomized versus 33% of conservatively treated dysglycemic patients showed glycemic improvement (difference 10%, 95% CI: -22% to 43%, not significant) 20% of adrenalectomized and 0% of conservatively treated dyslipidemic patients showed dyslipidemia improvement
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that while adrenalectomy for MACS improves hypertension, it does not reliably improve weight, glucose control, or lipid profiles compared to medical management. The modest and statistically nonsignificant differences in metabolic outcomes, alongside the open-label design and small sample, do not support adrenalectomy as a primary intervention for metabolic benefit in MACS at present.
A rigorous multicenter RCT with adequate follow-up that confirms prior findings but shows adrenalectomy offers limited benefit beyond hypertension for metabolic and QoL outcomes in MACS, with wide confidence intervals and modest effect sizes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that while adrenalectomy for MACS improves hypertension, it does not reliably improve weight, glucose control, or lipid profiles compared to medical management. The modest and statistically nonsignificant differences in metabolic outcomes, alongside the open-label design and small sample, do not support adrenalectomy as a primary intervention for metabolic benefit in MACS at present.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
OBJECTIVE: The CHIRACIC trail supported the beneficial effect of adrenalectomy on hypertension in patients with unilateral adrenal incidentalomas associated with mild autonomous cortisol secretion (MACS). Additional assessments evaluated the impact of adrenalectomy on body weight excess, metabolic abnormalities and quality of life. DESIGN: Multicenter superiority open-label randomized trial comparing adrenalectomy to conservative management. METHODS: Following a run-in phase to control hypertension, receive lifestyle advice and treatment for comorbidities, patients underwent a workup including measurement of BMI, visceral and total fat, fat mass, fasting blood glucose, HbA1c, oral glucose tolerance test, plasma lipids and quality of life (QoL). Following randomization, assessment of comorbidities and adaptation of their treatment were performed every 3 months for 13 months. Workup was repeated at the end of the study. RESULTS: Forty-eight patients were randomly assigned to adrenalectomy (n = 23) and conservative management (n = 25). 93%, 71% and 90% of patients were overweight/obese, prediabetics/diabetics and dyslipidemic, respectively. There was no statistically significant improvement in anthropometric and metabolic parameters after adrenalectomy as compared to conservative management: 21% and 4% of adrenalectomized and conservatively treated obese/overweight patients lost > 5% of body weight, respectively (difference 22%, 95%CI: -2% to 39%). Glycemic status improved in 44% and 33% of adrenalectomized and conservatively treated dysglycemic patients, respectively (difference 10%, 95%CI: -22% to 43%). Dyslipidemia improved in 20% of adrenalectomized and none of conservatively treated dyslipidemic patients. Changes in QoL were not different between groups. CONCLUSION: The beneficial effects of adrenalectomy on excess weight, metabolic disorders and QoL demonstrated in the CHIRACIC trial are more limited than those observed for hypertension. Additional randomized interventional studies involving a larger number of patients are needed to support the use of adrenalectomy in the treatment of these comorbidities.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.